High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor has been shown to be upregulated in breast cancers. VEGFR-1 and VEGFR-2 are the principal mediators of its effects. Together with VEGFR-1 and VEGFR-2, neuropilin-1 may act as a co-receptor for VEGF. Although VEGF exerts important effects on endothelial cells, VEGFRs are likely present on tumor cells as well. We used AQUA to analyze tumor-specific expression of VEGF, VEGFR-1, VEGFR-2, and neuropilin-1 on a large cohort breast cancer tissue microarray. Two-fold redundant arrays were constructed from 642 cases of primary breast adenocarcinomas. Automated image analysis with AQUA was then performed to determine a quantitative expression score. Scores from redundant arrays were normalized and averaged. Kaplan-Meier survival analysis showed that high levels of VEGF, VEGFR-1, VEGFR-2, and neuropilin-1 were all significantly associated with survival (Miller Siegmeund corrected P value 0.0020, 0.0160, and 0.0320 respectively). In addition, VEGF and neuropilin-1 retained a significant association with survival independent of other standard prognostic factors. VEGF, VEGFR-1 and 2, and neuropilin-1 are expressed to varying degrees in primary breast cancers and have prognostic significance. Further study of the functional significance of this finding is warranted as well as the prognostic value of these biomarkers in other tumor microenvironment-specific compartments (e.g. vessels).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744 · cited 1×
“Our program, X-tile, allows determination of an optimal cutpoint while correcting for the use of optimal P value statistics using the Miller-Siegmund P value correction [19].”
MethodSelf-citationVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687 · cited 1×
“functions in the physiologic and pathophysiologic regulation of endothelial cell (EC) growth and vascular permeability [1,2].”
BackgroundDangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143 · cited 1×
“If the last method (the so-called optimal P value approach) is used, a dramatic inflation of type I error rates can result [18].”
MethodRelf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 973
Automated subcellular localization and quantification of protein expression in tissue microarrays
Camp, R. L., Chung, G. G., & Rimm, D. L. (2002) · Nature Medicine · doi:10.1038/nm791 · Cited by 764 · cited 3×
“Staining tissue microarray slides for AQUA have been previously described [13].”
MethodSelf-citationBachelder, R. E., Crago, A. M., Chung, J., Wendt, M. A., Shaw, L. M., Robinson, G. S., & Mercurio, A. M. (2001) · PubMed · Cited by 487
Soker, S., Miao, H., Nomi, M., Takashima, S., & Klagsbrun, M. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10140 · Cited by 456 · cited 1×
“In regard to VEGF-mediated signaling, NP-1 appears to function by forming coreceptor complexes with VEGFR-1 and with VEGFR-2 [8,9].”
BackgroundToi, M., Inada, K., Suzuki, H., & Tominaga, T. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666040 · Cited by 362 · cited 1×
“Although immunohistochemistry-based studies seem less consistent, a number of studies have also found similar relationships between VEGF expression and outcome [20,22].”
ResultPsyrri, A., Yu, Z., Weinberger, P. M., Sasaki, C., Haffty, B., Camp, R., Rimm, D., & Burtness, B. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0420 · Cited by 269 · cited 1×
“(Original magnific biomarkers inmany different cancers [14-16].”
Self-citationThe role of neuropilins in cancer
Ellis, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0538 · Cited by 263 · cited 2×
“Although neuropilin expression has been described in a wide array of normal and developing tissue, its expression and regulation on vascular smooth cells and ECs (eg, up-regulation by ischemia and VEGF) suggest an important role in neoangiogensis [7].”
Background
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Modi, S. J., & Kulkarni, V. M. (2019) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2019.100009 · Cited by 320
Phage display screening of therapeutic peptide for cancer targeting and therapy
Saw, P. E., & Song, E.-W. (2019) · Protein & Cell · doi:10.1007/s13238-019-0639-7 · Cited by 279
Tabelin, C. B., Park, I., Phengsaart, T., Jeon, S., Villacorte-Tabelin, M., Alonzo, D., Yoo, K., Ito, M., & Hiroyoshi, N. (2021) · Resources, Conservation and Recycling · doi:10.1016/j.resconrec.2021.105610 · Cited by 278
Significance of immunohistochemistry in breast cancer
Zaha, D. C. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.382 · Cited by 277
Prud’homme, G. J., & Glinka, Y. (2012) · Oncotarget · doi:10.18632/oncotarget.626 · Cited by 275
Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
Larsen, A. K., Ouaret, D., El Ouadrani, K., & Petitprez, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.012 · Cited by 267
Roland, C. L., Dineen, S. P., Lynn, K. D., Sullivan, L. A., Dellinger, M. T., Sadegh, L., Sullivan, J. P., Shames, D. S., & Brekken, R. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0280 · Cited by 188
“Furthermore, expression of neuropilin-1 (Nrp-1) and Nrp-2, coreceptors for VEGF, is associated with poor prognosis in breast cancer (7), which might be due to coreceptor-mediated enhanced signaling through VEGFR2 (8).”
BackgroundNeuropilin‐1 expression in cancer and development
Jubb, A. M., Strickland, L. A., Liu, S. D., Mak, J., Schmidt, M., & Koeppen, H. (2012) · The Journal of Pathology · doi:10.1002/path.2989 · Cited by 188
Metadata
- Authors
- Ghosh, S., Sullivan, C. A. W., Zerkowski, M. P., Molinaro, A. M., Rimm, D. L., Camp, R. L., & Chung, G. G.
- Venue
- Human Pathology
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 39
- Issue
- 12
- Pages
- 1835-1843
- ISSN
- 0046-8177 (ISSN-L)
- OpenAlex
- W2020709543
- Cited by
- 182
- References
- 22
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.